Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Oklahoma judge...

    Oklahoma judge approves Teva Pharma USD 85 million opioid settlement

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-25T09:00:22+05:30  |  Updated On 16 Aug 2021 3:36 PM IST




    U.S: An Oklahoma judge on Monday approved a revised $85 million settlement with Teva Pharmaceutical Industries Ltd (Teva Pharma) resolving claims by the state's attorney general that the drugmaker helped fuel the U.S. opioid epidemic.

    The decision by Cleveland County District Judge Thad Balkman in Norman, Oklahoma came after the state's attorney general, governor and top lawmakers resolved a dispute over how the money should be deposited and spent.

    Oklahoma Attorney General Mike Hunter struck an initial settlement with Teva on May 26, just days before the Israel-based drugmaker was set to face trial alongside Johnson & Johnson, which is continuing to fight the case.

    Read Also: Teva Pharma to settle $85 million opioid claims of Oklahoma

    The settlement resolved claims that Teva and other drugmakers helped cause the epidemic by marketing opioids as safe and effective for everyday pain while downplaying their addictive qualities.

    The case is one of around 2,000 by state and local governments seeking to hold drugmakers responsible for an epidemic the U.S. Centers for Disease Control and Prevention says led to a record 47,600 opioid-related overdose deaths in 2017.

    Teva's deal came just days before the Israel-based drugmaker was set to face trial in the case, and two days after Oklahoma Governor Kevin Stitt signed a bill into law that required funds recovered in lawsuits by the state to be deposited into the state's treasury.

    The law followed criticism by state legislators that money from an earlier, $270 million settlement in the case with Purdue Pharma LP in March was not deposited in the state's coffers for lawmakers to determine its use.

    Instead, nearly $200 million of that March settlement went toward creating an addiction treatment and research centre at Oklahoma State University.

    Read Also: US states sue 20 drug firms including Teva Pharma over pricing cartel


    Under Teva's initial settlement, the $85 million was to be deposited into a court-controlled account pending the outcome of JnJ's trial.

    Hunter's office argued Teva's settlement should be combined with any money J&J must pay to help remedy, or abate, what the state says is a public nuisance that will cost $17.5 billion to remedy over 30 years. J&J denies the allegations.

    But Stitt and Republican leaders of the state's legislature argued any funds should be deposited directly with the state's treasury.

    Under the revised accord, money from Teva's settlement would be deposited in a fund with the state and only be used to address the opioid epidemic, subjected to future legislation, according to court papers. Teva did not admit wrongdoing.

    Read Also: USFDA nod to Teva generic nasal spray-Narcan to treat opioid overdose






    JnJJohnson & JohnsonMike HunterOklahomaOklahoma Attorney GeneralOklahoma judgeOklahoma State Universityopioid settlementopioidsPurdue PharmaTevaTeva PharmaceuticalThad BalkmanUS opioid epidemic
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok